HRP20220228T1 - Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom - Google Patents
Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom Download PDFInfo
- Publication number
- HRP20220228T1 HRP20220228T1 HRP20220228TT HRP20220228T HRP20220228T1 HR P20220228 T1 HRP20220228 T1 HR P20220228T1 HR P20220228T T HRP20220228T T HR P20220228TT HR P20220228 T HRP20220228 T HR P20220228T HR P20220228 T1 HRP20220228 T1 HR P20220228T1
- Authority
- HR
- Croatia
- Prior art keywords
- lymphoma
- combination
- use according
- hodgkin
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523861P | 2011-08-16 | 2011-08-16 | |
| EP11177658 | 2011-08-16 | ||
| US201261647539P | 2012-05-16 | 2012-05-16 | |
| US201261654097P | 2012-06-01 | 2012-06-01 | |
| EP12747923.6A EP2744515B1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti-cd19 antibody and a nitrogen mustard |
| PCT/EP2012/065906 WO2013024097A1 (en) | 2011-08-16 | 2012-08-14 | Combination therapy with an anti - cd19 antibody and a nitrogen mustard |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220228T1 true HRP20220228T1 (hr) | 2022-05-13 |
Family
ID=47714801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220228TT HRP20220228T1 (hr) | 2011-08-16 | 2012-08-14 | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140255427A1 (enExample) |
| EP (2) | EP2744515B1 (enExample) |
| JP (1) | JP6184952B2 (enExample) |
| KR (3) | KR20200058583A (enExample) |
| CN (1) | CN103732252B (enExample) |
| AU (1) | AU2012296907B2 (enExample) |
| BR (1) | BR112013033919B1 (enExample) |
| CA (2) | CA2841875C (enExample) |
| CY (1) | CY1125122T1 (enExample) |
| DK (1) | DK2744515T3 (enExample) |
| ES (1) | ES2909722T3 (enExample) |
| HR (1) | HRP20220228T1 (enExample) |
| HU (1) | HUE058350T2 (enExample) |
| IL (1) | IL230293B (enExample) |
| LT (1) | LT2744515T (enExample) |
| MX (1) | MX354479B (enExample) |
| PL (1) | PL2744515T3 (enExample) |
| PT (1) | PT2744515T (enExample) |
| RS (1) | RS63238B1 (enExample) |
| RU (1) | RU2625222C2 (enExample) |
| SG (1) | SG10201606785UA (enExample) |
| SI (1) | SI2744515T1 (enExample) |
| SM (1) | SMT202200159T1 (enExample) |
| WO (1) | WO2013024097A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015277516A1 (en) * | 2014-06-16 | 2016-12-22 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (CLL) |
| PL3302550T3 (pl) * | 2015-05-26 | 2020-02-28 | Morphosys Ag | Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania |
| SI3337506T1 (sl) | 2015-08-21 | 2021-12-31 | Morphosys Ag | Kombinacije in njihove uporabe |
| JP7208010B2 (ja) | 2016-03-29 | 2023-01-18 | ユニバーシティ オブ サザン カリフォルニア | 癌を標的とするキメラ抗原受容体 |
| SG11201810159TA (en) * | 2016-05-30 | 2018-12-28 | Morphosys Ag | Methods for predicting therapeutic benefit of anti-cd19 therapy in patients |
| IL266216B2 (en) | 2016-10-28 | 2023-09-01 | Morphosys Ag | Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof |
| WO2018102795A2 (en) | 2016-12-02 | 2018-06-07 | University Of Southern California | Synthetic immune receptors and methods of use thereof |
| IL270855B2 (en) | 2017-05-31 | 2023-03-01 | Morphosys Ag | A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax |
| KR20200030337A (ko) | 2018-09-12 | 2020-03-20 | 주식회사 녹십자랩셀 | 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물 |
| IL313736A (en) * | 2021-12-22 | 2024-08-01 | Incyte Corp | Treatment paradigm for CD19 antibody therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
| DK1071752T3 (da) * | 1998-04-21 | 2003-10-20 | Micromet Ag | CD19xCD3-specifikke polypeptider og anvendelsen deraf |
| HK1043312B (en) * | 1999-05-07 | 2006-07-28 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US20020058029A1 (en) | 2000-09-18 | 2002-05-16 | Nabil Hanna | Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| US20080260731A1 (en) * | 2002-03-01 | 2008-10-23 | Bernett Matthew J | Optimized antibodies that target cd19 |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| EP1814544A4 (en) | 2004-11-05 | 2009-12-02 | Cephalon Inc | CANCER TREATMENTS |
| AU2006262232A1 (en) | 2005-06-20 | 2007-01-04 | Medarex, Inc. | CD19 antibodies and their uses |
| CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
| JP5825756B2 (ja) * | 2006-08-14 | 2015-12-02 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ１９を標的とする最適化抗体 |
| AU2007294575B2 (en) | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
| DK2176298T3 (en) | 2007-05-30 | 2018-02-12 | Xencor Inc | Methods and compositions for inhibiting CD32B-expressing cells |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| US20110274697A1 (en) * | 2009-01-16 | 2011-11-10 | Cherry Teresa Thomas | Novel uses |
| SG173654A1 (en) | 2009-02-23 | 2011-09-29 | Glenmark Pharmaceuticals Sa | Humanized antibodies that bind to cd19 and their uses |
| CA2765080C (en) | 2009-06-24 | 2018-07-17 | The Feinstein Institute For Medical Research | Methods for treating chronic lymphocytic leukemia |
| TWI409079B (zh) * | 2009-08-14 | 2013-09-21 | Roche Glycart Ag | 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法 |
| CN102470172B (zh) * | 2009-08-14 | 2014-09-24 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与氟达拉滨和/或米托蒽醌的联合疗法 |
| MX2012005163A (es) * | 2009-11-06 | 2012-11-22 | Infinity Pharmaceuticals Inc | Formulaciones orales de un inhibidor de la ruta de hedgehog. |
-
2012
- 2012-08-14 EP EP12747923.6A patent/EP2744515B1/en active Active
- 2012-08-14 EP EP22155572.5A patent/EP4062936A1/en active Pending
- 2012-08-14 JP JP2014525434A patent/JP6184952B2/ja active Active
- 2012-08-14 PT PT127479236T patent/PT2744515T/pt unknown
- 2012-08-14 ES ES12747923T patent/ES2909722T3/es active Active
- 2012-08-14 BR BR112013033919-5A patent/BR112013033919B1/pt active IP Right Grant
- 2012-08-14 PL PL12747923T patent/PL2744515T3/pl unknown
- 2012-08-14 CA CA2841875A patent/CA2841875C/en active Active
- 2012-08-14 US US14/126,928 patent/US20140255427A1/en not_active Abandoned
- 2012-08-14 DK DK12747923.6T patent/DK2744515T3/da active
- 2012-08-14 CA CA3137321A patent/CA3137321A1/en active Pending
- 2012-08-14 HU HUE12747923A patent/HUE058350T2/hu unknown
- 2012-08-14 SG SG10201606785UA patent/SG10201606785UA/en unknown
- 2012-08-14 CN CN201280036571.XA patent/CN103732252B/zh active Active
- 2012-08-14 KR KR1020207014299A patent/KR20200058583A/ko not_active Withdrawn
- 2012-08-14 SI SI201231989T patent/SI2744515T1/sl unknown
- 2012-08-14 KR KR1020197026462A patent/KR102115203B1/ko active Active
- 2012-08-14 LT LTEPPCT/EP2012/065906T patent/LT2744515T/lt unknown
- 2012-08-14 HR HRP20220228TT patent/HRP20220228T1/hr unknown
- 2012-08-14 RS RS20220412A patent/RS63238B1/sr unknown
- 2012-08-14 AU AU2012296907A patent/AU2012296907B2/en active Active
- 2012-08-14 WO PCT/EP2012/065906 patent/WO2013024097A1/en not_active Ceased
- 2012-08-14 RU RU2014103492A patent/RU2625222C2/ru active
- 2012-08-14 KR KR1020147006936A patent/KR20140064873A/ko not_active Ceased
- 2012-08-14 MX MX2013014933A patent/MX354479B/es active IP Right Grant
- 2012-08-14 SM SM20220159T patent/SMT202200159T1/it unknown
-
2014
- 2014-01-02 IL IL230293A patent/IL230293B/en active IP Right Grant
-
2020
- 2020-04-03 US US16/839,777 patent/US20200353077A1/en not_active Abandoned
-
2022
- 2022-04-18 CY CY20221100289T patent/CY1125122T1/el unknown
-
2024
- 2024-01-12 US US18/411,350 patent/US20240366756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220228T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| HRP20220224T1 (hr) | Kombinacijska terapija s protutijelom anti-cd19 i dušičnim alkilirajućim agensom | |
| HRP20192100T1 (hr) | Kombinacija anti-cd19 antitijela i inhibitora brutonove tirozin kinaze i njene uporabe | |
| CL2022000328A1 (es) | Anticuerpo humanizado que se une específicamente al receptor de transferrina humano (tfr); composición farmacéutica; uso del anticuerpo humanizado para preparar un medicamento útil para tratar un trastorno neurológico. (divisional solicitud no. 3207-2017) | |
| HRP20211291T1 (hr) | Kombinacije i njihove primjene | |
| MX377410B (es) | Antagonistas de receptores de integrina y sus metodos de uso. | |
| GT201500105A (es) | Imidazo [1,2-a] piridincarboxamidas aminosustituidas y su uso | |
| CL2016000530A1 (es) | Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13). | |
| CY1121646T1 (el) | Παραγωγα μορφινανης για την αγωγη υπερβολικης δοσης ναρκωτικων | |
| EP4353747A3 (en) | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer | |
| AR124500A2 (es) | Aumento de la biodisponibilidad de droga en terapia naltrexona | |
| ECSP11011403A (es) | Derivado de benzodiazepina para el tratamiento de neoplasma hematopoyetico y leucemia | |
| BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| HRP20210838T1 (hr) | Kombinacija protutijela anti-cd19 s inhibitorom bcl-2 te njihove uporabe | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX392618B (es) | Un anticuerpo monoclonal de anti-beta7 para usarse en el tratamiento de un trastorno inflamatorio gastrointestinal. | |
| CL2013003298A1 (es) | Uso de metotrexato porque sirve para preparar un medicamento, útil en el tratamiento de enfermedades que necesiten tratamiento con un producto terapéutico que produzca autoinmunidad, administrado en un sólo ciclo. | |
| RU2015134422A (ru) | Применение левоцитиризина и монтелукаста при лечении васкулита | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| JP2019533682A5 (enExample) | ||
| AR084093A1 (es) | Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica | |
| CY1117854T1 (el) | Πεπτιδικη φαρμακοτεχνικη μορφη για τοπικη οφθαλμικη χρηση | |
| WO2017181099A8 (en) | Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith | |
| AR066778A1 (es) | Terapia combinada para el tratamiento del cancer que comprende vinflunina y trastuzumab |